Screening and Diagnostics

The common application of routine cervical cancer selection has significantly enhanced physicians' skill to detect cancerous and precancerous changes of the cervix. Globally, the human papillomavirus (HPV) has been distinguished in as many as 99.7% of cervical cancer. It is assessed that 50% of women analyzed with invasive cervical cancer have never had a Papanicolaou test, and 10% have not had a Papanicolaou test in the 5 years prior to diagnosis. Sadly, despite widespread screening and treatment of pre-invasive lesions, there are still approximately 12,000 new cases of cervical cancer in the United Kingdom each year and roughly 4,000 annual deaths from the disease. Pregnancy tests are done by detecting human chorionic gonadotropin. The treatment of pregnancy involves a multifaceted approach using 3 main diagnostic tools i.e. history and physical examination, laboratory evaluation, and ultrasonography.

    Related Conference of Screening and Diagnostics

    September 23-24, 2019

    2nd World Summit on Liver Cirrhosis and Hepatitis

    Tokyo, Japan
    October 14-15, 2019

    19th World Gastroenterologists Summit

    Sydney, Australia
    October 23-24, 2019

    World Congress on Pancreatic Cancer and Liver Diseases

    | Tokyo, Japan
    November 18-19, 2019

    20th World Congress on Gastroenterology

    Rome, Italy
    December 02-03, 2019

    International Conference on Infectious Diseases in Gynecology and Obstetrics

    | Radisson Hotel Narita | Tokyo, Japan
    June 24-25, 2020

    15th Euro-Global Gastroenterology Conference


    Screening and Diagnostics Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in